| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
|
Piotrowska, Z.
|
|
|
29 |
10 |
p. 2092-2097
|
article
|
| 2 |
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
|
Staehler, M.
|
|
|
29 |
10 |
p. 2098-2104
|
article
|
| 3 |
Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out
|
Procopio, G.
|
|
|
29 |
10 |
p. 2030-2032
|
article
|
| 4 |
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
|
Paré, L.
|
|
|
29 |
10 |
p. 2121-2128
|
article
|
| 5 |
Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers
|
Chen, X.
|
|
|
29 |
10 |
p. 2046-2051
|
article
|
| 6 |
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2
|
Chang, K.
|
|
|
29 |
10 |
p. 2061-2067
|
article
|
| 7 |
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|
Curigliano, G.
|
|
|
29 |
10 |
p. 2153
|
article
|
| 8 |
Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
|
Tan, W.W.
|
|
|
29 |
10 |
p. 2150
|
article
|
| 9 |
correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
|
Shi, W.
|
|
|
29 |
10 |
p. 2152
|
article
|
| 10 |
Correction to: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
|
Loibl, S.
|
|
|
29 |
10 |
p. 2151
|
article
|
| 11 |
Editorial Board
|
|
|
|
29 |
10 |
p. i-ii
|
article
|
| 12 |
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
|
Tan, A.C.
|
|
|
29 |
10 |
p. 2115-2120
|
article
|
| 13 |
Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor
|
Kunimasa, K.
|
|
|
29 |
10 |
p. 2145-2147
|
article
|
| 14 |
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
|
Thomas, M.
|
|
|
29 |
10 |
p. 2076-2084
|
article
|
| 15 |
Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed
|
Smyth, E.C.
|
|
|
29 |
10 |
p. 2027-2028
|
article
|
| 16 |
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
|
Kron, A.
|
|
|
29 |
10 |
p. 2068-2075
|
article
|
| 17 |
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
|
Krug, A.K.
|
|
|
29 |
10 |
p. 2143
|
article
|
| 18 |
Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection
|
Scully, E.P.
|
|
|
29 |
10 |
p. 2141-2142
|
article
|
| 19 |
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II
|
Dietz, A.
|
|
|
29 |
10 |
p. 2105-2114
|
article
|
| 20 |
‘Optimism bias’ in contemporary national clinical trial network phase III trials: are we improving?
|
Zakeri, Kaveh
|
|
|
29 |
10 |
p. 2135-2139
|
article
|
| 21 |
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
|
Sabari, J.K.
|
|
|
29 |
10 |
p. 2085-2091
|
article
|
| 22 |
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
|
Bang, Y.-J
|
|
|
29 |
10 |
p. 2052-2060
|
article
|
| 23 |
Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma
|
Sathasivam, H.P.
|
|
|
29 |
10 |
p. 2144-2145
|
article
|
| 24 |
Reply to the letter to the editor ‘Small repeated boluses are unreliable to provide rapid analgesia with intravenous morphine titration and mislead conversion ratio to oral morphine’ by Mercadante S.
|
Fallon, M.
|
|
|
29 |
10 |
p. 2148-2149
|
article
|
| 25 |
Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
|
Ogale, S.
|
|
|
29 |
10 |
p. 2140
|
article
|
| 26 |
Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication
|
Liang, F.
|
|
|
29 |
10 |
p. 2129-2134
|
article
|
| 27 |
Small repeated boluses are unreliable to provide rapid analgesia with intravenous morphine titration and mislead conversion ratio to oral morphine
|
Mercadente, S.
|
|
|
29 |
10 |
p. 2147-2148
|
article
|
| 28 |
Table of Contents
|
|
|
|
29 |
10 |
p. iii-v
|
article
|
| 29 |
Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer
|
Mauri, G.
|
|
|
29 |
10 |
p. 2143-2144
|
article
|
| 30 |
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer
|
Costa, D.B.
|
|
|
29 |
10 |
p. 2028-2030
|
article
|
| 31 |
Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018
|
Stiefel, F.
|
|
|
29 |
10 |
p. 2033-2036
|
article
|
| 32 |
Translational insights into gastrointestinal stromal tumor and current clinical advances
|
Hemming, M.L.
|
|
|
29 |
10 |
p. 2037-2045
|
article
|
Journal description